First-Line Selpercatinib in RET Fusion-Positive NSCLC

Progression-free survival was longer with selpercatinib than with platinum-based chemotherapy plus pemetrexed with or without pembrolizumab.

Saved in:
Bibliographic Details
Published inNEJM journal watch. Oncology & hematology
Main Author Patel, Jyoti D
Format Journal Article
LanguageEnglish
Published Waltham Massachusetts Medical Society 01.12.2023
Subjects
Chemotherapy
Online AccessGet full text

Cover

More Information
Summary:Progression-free survival was longer with selpercatinib than with platinum-based chemotherapy plus pemetrexed with or without pembrolizumab.
ISSN:2330-0426